Document is current
Any future updates will be listed below
-
Authors
Ambrosen, Karen S. https://orcid.org/0000-0002-5638-2357
Fredriksson, Fanny
Anhøj, Simon
Bak, Nikolaj
van Dellen, Edwin
Dominicus, Livia
Lemvigh, Cecilie K.
Sørensen, Mikkel E.
Nielsen, Mette Ø.
Bojesen, Kirsten B.
Fagerlund, Birgitte
Glenthøj, Birte Y.
Oranje, Bob
Hansen, Lars K.
Ebdrup, Bjørn H.
-
Funding
Funding for this research was provided by:
Lundbeckfonden (R25-A2701, R155-2013-16337)
ZonMw (60-63600-98-711)
- License Information
-
More Information
Article History
Received: 11 August 2022
Accepted: 9 January 2023
First Online: 2 February 2023
Declarations
:
: BHE has received lecture fees and/or is part of Advisory Boards of Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Otsuka Pharma Scandinavia AB, Takeda Pharmaceutical Company, Boehringer Ingelheim, and Lundbeck Pharma A/S. BYG is the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. She has no other conflicts to disclose. NB is employed by H. Lundbeck A/S. KBB received lecture fee from Lundbeck Pharma A/S. The remaining authors have nothing to disclose.
: The studies were approved by the Regional Danish Committee on Health Research Ethics (H-D-2008-088, H-3-2013-149) and conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: All participants provided written informed consent.
